Last edition
News about "Daiichi Sankyo"
CHMP Recommends T-DXd EU Approval in HER2-Low/Ultralow Breast Cancer
ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.
Daiichi Sankyo | 04/03/2025 | By Aishwarya
Alteogen Signs Exclusive License Deal with Daiichi Sankyo to Develop Subcutaneous ENHERTU
Under the terms of the agreement, Daiichi Sankyo will acquire world-wide rights to use ALT-B4, Alteogen's novel hyaluronidase utilizing Hybrozyme Technology, to develop and commercialize a subcutaneous version of ENHERTU (fam-trastuzumab deruxtecan-nxki).
Daiichi Sankyo | 11/11/2024 | By Aishwarya | 169
Daiichi Sankyo's quizartinib plus chemotherapy improves OS in patients with AML
Quizartinib combined with standard induction and consolidation chemotherapy and then continued as a single agent demonstrated a 22.4 per cent reduction in the risk of death
Daiichi Sankyo | 13/06/2022 | By Sudeep Soparkar | 560
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy